167 related articles for article (PubMed ID: 36091760)
41. Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036.
Chan WW; Wise SC; Kaufman MD; Ahn YM; Ensinger CL; Haack T; Hood MM; Jones J; Lord JW; Lu WP; Miller D; Patt WC; Smith BD; Petillo PA; Rutkoski TJ; Telikepalli H; Vogeti L; Yao T; Chun L; Clark R; Evangelista P; Gavrilescu LC; Lazarides K; Zaleskas VM; Stewart LJ; Van Etten RA; Flynn DL
Cancer Cell; 2011 Apr; 19(4):556-68. PubMed ID: 21481795
[TBL] [Abstract][Full Text] [Related]
42. Role of treatment in the appearance and selection of BCR-ABL1 kinase domain mutations.
Razga F; Jurcek T; Zackova D; Dvorakova D; Toskova M; Jeziskova I; Mayer J; Racil Z
Mol Diagn Ther; 2012 Aug; 16(4):251-9. PubMed ID: 22873741
[TBL] [Abstract][Full Text] [Related]
43. Which tyrosine-kinase inhibitor to use first in chronic phase chronic myelogenous leukemia?
Mace ML; Dahl J; Jabbour EJ
Expert Opin Pharmacother; 2015 May; 16(7):999-1007. PubMed ID: 25840461
[TBL] [Abstract][Full Text] [Related]
44. A coiled-coil mimetic intercepts BCR-ABL1 dimerization in native and kinase-mutant chronic myeloid leukemia.
Woessner DW; Eiring AM; Bruno BJ; Zabriskie MS; Reynolds KR; Miller GD; O'Hare T; Deininger MW; Lim CS
Leukemia; 2015 Aug; 29(8):1668-75. PubMed ID: 25721898
[TBL] [Abstract][Full Text] [Related]
45. Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors.
Pietarinen PO; Eide CA; Ayuda-Durán P; Potdar S; Kuusanmäki H; Andersson EI; Mpindi JP; Pemovska T; Kontro M; Heckman CA; Kallioniemi O; Wennerberg K; Hjorth-Hansen H; Druker BJ; Enserink JM; Tyner JW; Mustjoki S; Porkka K
Oncotarget; 2017 Apr; 8(14):22606-22615. PubMed ID: 28186983
[TBL] [Abstract][Full Text] [Related]
46. Standard treatment of Ph+ CML in 2010: how, when and where not to use what BCR/ABL1 kinase inhibitor?
Valent P
Eur J Clin Invest; 2010 Oct; 40(10):918-31. PubMed ID: 20597967
[TBL] [Abstract][Full Text] [Related]
47. Inhibition of isoprenylcysteine carboxylmethyltransferase augments BCR-ABL1 tyrosine kinase inhibition-induced apoptosis in chronic myeloid leukemia.
Sun WT; Xiang W; Ng BL; Asari K; Bunte RM; Casey PJ; Wang M; Chuah C
Exp Hematol; 2016 Mar; 44(3):189-93.e2. PubMed ID: 26706195
[TBL] [Abstract][Full Text] [Related]
48. Plasma tyrosine kinase activity as a potential biomarker in BCR-ABL1-targeted therapy.
Yeh CH; Abdool A; Bruey JM
Cancer Biomark; 2010; 7(6):295-303. PubMed ID: 21694468
[TBL] [Abstract][Full Text] [Related]
49. Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia.
Eiring AM; Page BDG; Kraft IL; Mason CC; Vellore NA; Resetca D; Zabriskie MS; Zhang TY; Khorashad JS; Engar AJ; Reynolds KR; Anderson DJ; Senina A; Pomicter AD; Arpin CC; Ahmad S; Heaton WL; Tantravahi SK; Todic A; Moriggl R; Wilson DJ; Baron R; O'Hare T; Gunning PT; Deininger MW
Leukemia; 2015 Mar; 29(3):586-597. PubMed ID: 25134459
[TBL] [Abstract][Full Text] [Related]
50. Sphingosine kinase-1 and sphingosine 1-phosphate receptor 2 mediate Bcr-Abl1 stability and drug resistance by modulation of protein phosphatase 2A.
Salas A; Ponnusamy S; Senkal CE; Meyers-Needham M; Selvam SP; Saddoughi SA; Apohan E; Sentelle RD; Smith C; Gault CR; Obeid LM; El-Shewy HM; Oaks J; Santhanam R; Marcucci G; Baran Y; Mahajan S; Fernandes D; Stuart R; Perrotti D; Ogretmen B
Blood; 2011 Jun; 117(22):5941-52. PubMed ID: 21527515
[TBL] [Abstract][Full Text] [Related]
51. Modelling ponatinib resistance in tyrosine kinase inhibitor-naïve and dasatinib resistant
Lu L; Kok CH; Saunders VA; Wang J; McLean JA; Hughes TP; White DL
Oncotarget; 2018 Oct; 9(78):34735-34747. PubMed ID: 30410673
[TBL] [Abstract][Full Text] [Related]
52. Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia.
Soverini S; de Benedittis C; Mancini M; Martinelli G
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S120-8. PubMed ID: 26297264
[TBL] [Abstract][Full Text] [Related]
53. MPT0B002, a novel microtubule inhibitor, downregulates T315I mutant Bcr-Abl and induces apoptosis of imatinib-resistant chronic myeloid leukemia cells.
Yeh YY; Liou JP; Lee YL; Lin JY; Huang HM
Invest New Drugs; 2017 Aug; 35(4):427-435. PubMed ID: 28349229
[TBL] [Abstract][Full Text] [Related]
54. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring.
Jabbour E; Kantarjian H
Am J Hematol; 2020 Jun; 95(6):691-709. PubMed ID: 32239758
[TBL] [Abstract][Full Text] [Related]
55. A novel BCR-ABL1 fusion gene identified by next-generation sequencing in chronic myeloid leukemia.
Lyu X; Yang J; Wang X; Hu J; Liu B; Zhao Y; Guo Z; Liu B; Fan R; Song Y
Mol Cytogenet; 2016; 9():47. PubMed ID: 27350795
[TBL] [Abstract][Full Text] [Related]
56. MXD1 regulates the imatinib resistance of chronic myeloid leukemia cells by repressing BCR-ABL1 expression.
Huan C; Jin L; Heng W; Na A; Yuming P; Xin D; Qiaoxia Z
Leuk Res; 2018 Dec; 75():1-6. PubMed ID: 30419548
[TBL] [Abstract][Full Text] [Related]
57. Clinical implications of conventional cytogenetics, fluorescence in situ hybridization (FISH) and molecular testing in chronic myeloid leukaemia patients in the tyrosine kinase inhibitor era - A review.
Ankathil R; Ismail SM; Mohd Yunus N; Sulong S; Husin A; Abdullah AD; Hassan R
Malays J Pathol; 2020 Dec; 42(3):307-321. PubMed ID: 33361712
[TBL] [Abstract][Full Text] [Related]
58. Inhibition of PI3K/mTOR overcomes nilotinib resistance in BCR-ABL1 positive leukemia cells through translational down-regulation of MDM2.
Ding J; Romani J; Zaborski M; MacLeod RA; Nagel S; Drexler HG; Quentmeier H
PLoS One; 2013; 8(12):e83510. PubMed ID: 24349524
[TBL] [Abstract][Full Text] [Related]
59. Anthelmintic niclosamide suppresses transcription of BCR-ABL fusion oncogene via disabling Sp1 and induces apoptosis in imatinib-resistant CML cells harboring T315I mutant.
Jin B; Wang C; Shen Y; Pan J
Cell Death Dis; 2018 Jan; 9(2):68. PubMed ID: 29358661
[TBL] [Abstract][Full Text] [Related]
60. Efficacy of tyrosine kinase inhibitors on a mouse chronic myeloid leukemia model and chronic myeloid leukemia stem cells.
Tanaka Y; Fukushima T; Mikami K; Adachi K; Fukuyama T; Goyama S; Kitamura T
Exp Hematol; 2020 Oct; 90():46-51.e2. PubMed ID: 32910995
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
